Bruker Co. (NASDAQ:BRKR) CEO Frank H. Laukien purchased 73,000 shares of the firm’s stock in a transaction on Thursday, May 18th. The shares were purchased at an average cost of $26.22 per share, for a total transaction of $1,914,060.00. Following the completion of the purchase, the chief executive officer now directly owns 37,750,851 shares in the company, valued at $989,827,313.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 3rd. The medical research company reported $0.19 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.19. Bruker had a return on equity of 27.77% and a net margin of 9.53%. The company had revenue of $384.90 million for the quarter, compared to analysts’ expectations of $372.59 million. During the same quarter in the previous year, the business posted $0.21 EPS. The business’s revenue for the quarter was up 2.5% on a year-over-year basis.

Insider Buying and Selling by Quarter for Bruker (NASDAQ:BRKR)

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 23rd. Shareholders of record on Monday, June 5th will be paid a dividend of $0.04 per share. The ex-dividend date of this dividend is Thursday, June 1st. This represents a $0.16 annualized dividend and a yield of 0.61%. Bruker’s dividend payout ratio (DPR) is presently 16.84%.

WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/05/19/bruker-co-brkr-ceo-purchases-1914060-00-in-stock.html.

Several equities research analysts have issued reports on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Bruker in a research note on Monday. Deutsche Bank AG raised their price target on shares of Bruker from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Monday. Cowen and Company increased their price objective on shares of Bruker from $25.00 to $27.00 and gave the stock a “market perform” rating in a report on Thursday, May 4th. BTIG Research reiterated a “hold” rating on shares of Bruker in a report on Wednesday, February 15th. Finally, Cantor Fitzgerald set a $28.00 price objective on shares of Bruker and gave the stock a “buy” rating in a report on Tuesday, February 14th. Twelve equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.

A number of institutional investors have recently added to or reduced their stakes in BRKR. Point72 Asset Management L.P. boosted its position in Bruker by 2,261.9% in the first quarter. Point72 Asset Management L.P. now owns 1,152,600 shares of the medical research company’s stock valued at $26,890,000 after buying an additional 1,103,800 shares during the period. Blue Sky Asset Management LLC purchased a new stake in shares of Bruker during the first quarter valued at approximately $1,217,000. Tudor Investment Corp ET AL purchased a new stake in shares of Bruker during the first quarter valued at approximately $367,000. Sensato Investors LLC boosted its stake in shares of Bruker by 52.2% in the first quarter. Sensato Investors LLC now owns 123,100 shares of the medical research company’s stock valued at $2,872,000 after buying an additional 42,200 shares during the last quarter. Finally, Gotham Asset Management LLC boosted its stake in shares of Bruker by 265.8% in the first quarter. Gotham Asset Management LLC now owns 48,721 shares of the medical research company’s stock valued at $1,137,000 after buying an additional 35,401 shares during the last quarter. 69.45% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Company’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST).

5 Day Chart for NASDAQ:BRKR

Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with MarketBeat.com's FREE daily email newsletter.